

As per the request of the Editorial Board, we have revised the manuscript to include the findings of the recently published IRIS trial (NEJM 2016). This pioglitazone trial, the largest since the 2005 PROactive trial, reported an imbalance in the number of bladder cancer cases between patients randomized to pioglitazone versus placebo. We believe that these findings are timely, and strengthen our overall conclusions. This can be found in the Discussion section (Page 17, second paragraph).